Aryland heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
Details for Australian Patent Application No. 2008251557 (hide)
International Classifications
Event Publications
26 November 2009 PCT application entered the National Phase
PCT publication WO2008/141081 Priority application(s): WO2008/141081
7 October 2010 Assignment before Grant
AMR Technology, Inc.; Bristol-Myers Squibb Company The application has been assigned to Bristol-Myers Squibb Company; Albany Molecular Research, Inc.
27 September 2012 Amendment Made
The nature of the amendment is: Amend the name of the inventor to read Molino, Bruce F.; Liu, Shuang; Cui, Wenge; Guzzo, Peter R.; Olson, Richard E. and Yet, Larry 2009
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2008251556-Membrane module with multiple bottom headers and filtration process
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
![](/images/main/3dbox_small.png)
- Editable Word format reports
- For IP Professionals
- Multiuser